AHK-Cu vs Tesamorelin
Well Studied vs FDA Approved
synergistic Mechanism-based · 47% AHK-Cu and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
AHK-Cu Tesamorelin
Weight 416.9 Da 5,135.9 Da
Half-life Not established 26-38 minutes
Chain 3 amino acids 44 amino acids
Type Copper tripeptide complex GHRH analog
Key Benefits
AHK-Cu
01 Hair follicle elongation stimulation
02 Dermal papilla cell proliferation
03 VEGF upregulation for improved scalp circulation
04 TGF-β1 reduction (counters DHT effects)
05 Anti-apoptotic protection for follicles
06 Collagen synthesis support
07 Convenient topical application
08 Fibroblast activation for skin regeneration
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
AHK-Cu
0.5-1% topical solution/serum / Once or twice daily application
Mesotherapy - Scalp (Practitioner) 0.1-0.5 mg per injection site Weekly sessions
Research Protocol 1-5 mg 2-3 times weekly
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
AHK-Cu
Generally well-tolerated with excellent safety profile in topical applications
Rare scalp irritation (patch test recommended)
Potential for mild redness on sensitive skin
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Not for use on broken or infected skin
Avoid eye area - may cause irritation
Do not use if allergic to copper or peptides
Not recommended during acute skin infections
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
AHK-Cu Tesamorelin
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest March 2025 June 2025
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.